Investigational drug · Phase 2
Pirmitegravir
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV-1-infection.
Phase 2Last checked: Nov 20, 2026Latest source record: May 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "Pirmitegravir"
First trial start
2023
May 23, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pirmitegravir", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV-1-infection
Approved drugs for the same conditions: HIV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Pirmitegravir" as an intervention, largest first.
ST Pharm Co., Ltd.Industry
NCT05869643 · 25 participants · Start May 23, 2023 · Primary completion Apr 25, 2026
Drug: Low-dose STP0404 (Pirmitegravir); Medium-dose STP0404 (Pirmitegravir) and 2 more · For: HIV-1-infection
Sites: Los Angeles, California; Ft. Pierce, Florida; Miami, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Erratum for Dinh et al., "The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir".
Dinh T, Tber Z, Rey JS, et al. · mBio 2025
- The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir.
Dinh T, Tber Z, Rey JS, et al. · mBio 2024
- The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir.
Dinh T, Tber Z, Rey JS, et al. · bioRxiv 2024
- The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function.
Singer MR, Dinh T, Levintov L, et al. · mBio 2023
Also in development for HIV-1-infection
- GS-3242Phase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- LEN FDCPhase 33 trials
Gilead Sciences · HIV-1-infection, HIV-1 Infection
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- OBRPhase 32 trials
Gilead Sciences · HIV-1-infection
- TMB-365TMB-380, VRC07523LSPhase 23 trials
TaiMed Biologics Inc. · HIV-1-infection, HIV -1 Infection
- CAP256V2LSPhase 21 trial
Gilead Sciences · HIV-1-infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.